Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells

Cancer Letters

Volumn 252, Issue 1, 2007, Pages 75-85

  Ju, Dong Sik ^a   Kim, Mi Ju ^a   Bae, Jae Ho ^a   Song, Hye Soon ^a   Chung, Byung Seon ^a   Lee, Min Ki ^a   Kang, Chi Dug ^a,b   Lee, Hyun Sun ^c   Kim, Dong Wan ^d   Kim, Sun Hee ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c Busan Medical Center   (South Korea)

^d Changwon National University   (South Korea)

Author keywords

Bcr Abl; Camptothecin; Combination; DNA PK; Imatinib; Resistance

Indexed keywords

BCR ABL PROTEIN; BRCA1 PROTEIN; CALCIUM BINDING PROTEIN; CAMPTOTHECIN; DNA; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPERSENSITIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BRCA1 PROTEIN; CAMPTOTHECIN; CELL LINE, TUMOR; DNA REPAIR ENZYMES; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NUCLEAR PROTEINS; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RADIATION TOLERANCE;

EID: 34248383678     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.013     Document Type: Article

References (46)

1. Sawyers C.L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12 (2002) 111-115
2. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344 (2001) 1031-1037
3. Onida F., Ball G., Kantarjian H.M., Smith T.L., Glassman A., Albitar M., et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 95 (2002) 1673-1684
4. Dai Y., Rahmani M., Corey S.J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279 (2004) 34227-34239
5. Nimmanapalli R., O'Bryan E., Huang M., Bali P., Burnette P.K., Loughran T., et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 62 (2002) 5761-5769
6. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64 (2004) 672-677
7. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21 (2002) 8591-8604
8. Czechowska A., Poplawski T., Drzewoski J., and Blasiak J. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. Chem. Biol. Interact. 152 (2005) 139-150
9. Majsterek I., Sliwinski T., Poplawski T., Pytel D., Kowalski M., Slupianek A., et al. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat. Res. 603 (2006) 74-82
10. Slupianek A., Nowicki M.O., Koptyra M., and Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst.) 5 (2006) 243-250
11. Majsterek I., Blasiak J., Mlynarski W., Hoser G., and Skorski T. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?. Cell Biol. Int. 26 (2002) 363-370
12. Hoser G., Majsterek I., Romana D.L., Slupianek A., Blasiak J., and Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?. Leuk. Res. 27 (2003) 267-273
13. Deriano L., Guipaud O., Merle-Beral H., Binet J.L., Ricoul M., Potocki-Veronese G., et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105 (2005) 4776-4783
14. Nowicki M.O., Falinski R., Koptyra M., Slupianek A., Stoklosa T., Gloc E., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104 (2004) 3746-3753
15. Muller C., and Salles B. Regulation of DNA-dependent protein kinase activity in leukemic cells. Oncogene 15 (1997) 2343-2348
16. Essers J., van Steeg H., de Wit J., Swagemakers S.M., Vermeij M., Hoeijmakers J.H., et al. Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J. 19 (2000) 1703-1710
17. P Jackson S. Sensing and repairing DNA double-strand breaks. Carcinogenesis 23 (2002) 687-696
18. Kurimasa A., Kumano S., Boubnov N.V., Story M.D., Tung C.S., Peterson S.R., et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol. Cell. Biol. 19 (1999) 3877-3884
19. Sawada M., Sun W., Hayes P., Leskov K., Boothman D.A., and Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5 (2003) 320-329
20. Kim S.H., Kim D., Han J.S., Jeong C.S., Chung B.S., Kang C.D., et al. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res. 59 (1999) 4012-4017
21. Gullo C., Au M., Feng G., and Teoh G. The biology of Ku and its potential oncogenic role in cancer. Biochim. Biophys. Acta 1765 (2006) 223-234
22. Frit P., Canitrot Y., Muller C., Foray N., Calsou P., Marangoni E., et al. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-ichlorodiammineplatinum(II): role of Ku autoantigen. Mol. Pharmacol. 56 (1999) 141-146
23. Salles B., Calsou P., Frit P., and Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol. Biol. (Paris) 54 (2006) 185-193
24. Kashishian A., Douangpanya H., Clark D., Schlachter S.T., Eary C.T., Schiro J.G., et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol. Cancer Ther. 2 (2003) 1257-1264
25. Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M.Z., Wen S.C., Zon G., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86 (1995) 726-736
26. Klejman A., Rushen L., Morrione A., Slupianek A., and Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21 (2002) 5868-5876
27. Yoshida C., and Melo J.V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol. 79 (2004) 420-433
28. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97 (2001) 1999-2007
29. Liu W.M., Stimson L.A., and Joe S.P. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive CML cells: synergistic interactions with antileukaemia agents. Br. J. Cancer 86 (2002) 1472-1478
30. Kehrer D.F., Soepenberg O., Loos W.J., Verweij J., and Sparreboom A. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 12 (2001) 89-105
31. Horowitz R.W., Wadler S., and Wiernik P.H. A review of the clinical experience with irinotecan (CPT-11). Am. J. Ther. 4 (1997) 203-210
32. Abdel-Aziz W., Hickey R.J., and Malkas L.H. An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents. Biochem. Pharmacol. 68 (2004) 11-21
33. Khobta A., Ferri F., Lotito L., Montecucco A., Rossi R., and Capranico G. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. Mol. Biol. 357 (2006) 127-138
34. Wu J., Yin M.B., Hapke G., Toth K., and Rustum Y.M. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxycamptothecin. Mol. Pharmacol. 61 (2002) 742-748
35. Johnson F.M., Krug L.M., Tran H.T., Shoaf S., Prieto V.G., Tamboli P., Peeples B., Patel J., and Glisson B.S. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 106 (2006) 366-374
36. Jin S., Inoue S., and Weaver D.T. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase. Carcinogenesis 19 (1998) 965-971
37. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., and Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18 (1999) 1397-1406
38. Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., and Rowinsky E.K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 88 (1996) 734-741
39. Su J., and Ciftci K. Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells. Int. J. Biochem. Cell Biol. 34 (2002) 950-957
40. Hesling C., D'Incan M., D'Incan C., Souteyrand P., Monboisse J.C., Pasco S., et al. Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression. J. Invest Dermatol. 122 (2004) 369-380
41. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Pquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
42. le Coutre P., Tassi E., Varella-Garcia M., Barni R., Mologni L., Cabrita G., et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95 (2000) 1758-1766
43. Someya M., Sakata K., Matsumoto Y., Yamamoto H., Monobe M., Ikeda H., et al. The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 27 (2006) 117-122
44. Chen G.G., Sin F.L., Leung B.C., Ng H.K., and Poon W.S. Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death. J. Cell Physiol. 203 (2005) 127-132
45. Brady N., Gaymes T.J., Cheung M., Mufti G.J., and Rassool F.V. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res. 63 (2003) 1798-1805
46. Yang S.H., Nussenzweig A., Li L., Kim D., Ouyang H., Burgman P., et al. Modulation of thermal induction of Hsp70 expression by Ku autoantigen or its individual subunits. Mol. Cell Biol. 16 (1996) 3799-3806